

January 14, 2020



Endonovo Therapeutics Announces Issuance of Broad Patent Covering Electromagnetic Treatment of Multiple Sclerosis

- *This furthers Endonovo's strategy to commercialize and protect its Electroceutical(s)[®]*

Los Angeles, CA, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent for Application No. 15/549,748 covering method and apparatus for electromagnetic treatment of multiple sclerosis.

"This issuance follows our prior patents related to the methods of treating post-operative pain and edema," said Dr. Nev Zubcevik, Endonovo's Chief Medical Officer and Harvard trained Physical Medicine and Rehabilitation specialist. "The SofPulse[®] technology is research proven and universally applicable to inflammatory conditions. Our preliminary research in the field of Autoimmune Encephalomyelitis - the inflammatory autoimmune model of multiple sclerosis, reveals significant change in the EAE score of treated animals when compared to sham. We are looking forward to expanding our technology applications into neuroinflammatory disorders; we believe our growing patent portfolio reinforces Endonovo's leadership position in utilizing SofPulse[®] to address pain while also underscoring the pioneering nature of the company's Pulsed Electromagnetic Field-based (PEMF) Electroceuticals[®]."

Alan Collier, Chief Executive Officer stated, "Our platform provides a unique opportunity for understanding the benefits Electroceuticals[®] can deliver in a wide range of areas. Over the course of the past three years, Endonovo has grown its intellectual property in a rapid and methodical manner and we believe well positions us to extend our advantage in harnessing the power of Pulsed Electromagnetic Field (PEMF) Electroceuticals[®]."

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals[®] therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals[®] therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical[®] therapeutic device, SofPulse[®], using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals[®] therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals[®] therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its

future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Endonovo Therapeutics, Inc.

Mr. Andrew Barwicki

516-662-9461

Andrew@barwicki.com

www.endonovo.com



Source: Endonovo Therapeutics, Inc.